Targeting the serine protease PCSK9 via covalent complementarity
Targeting the serine protease PCSK9 via covalent complementarity
批准号:
8541644
负责人:
John S Chorba
金额:
$5.38万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-09 至 2014-06-30
关键词:
Active SitesAtherosclerosisBasic ScienceBindingBiochemicalBiologyCaliforniaCardiovascular systemCell secretionChemicalsClinicClinical TrialsCountryCysteineDevelopmentDiseaseDistantDominant-Negative MutationEngineeringEnzymesEpidemiologyFamilyGeneticGenetic PolymorphismGleanGoalsHeart DiseasesIn VitroInstructionLDL Cholesterol LipoproteinsLigandsLow Density Lipoprotein ReceptorLow-Density LipoproteinsLysosomesMediatingMethodsModificationMolecular ChaperonesMorbidity - disease rateMutationNatureOutcomePeptide HydrolasesPlayPopulationProcessProprotein Convertase 1Proprotein Convertase 2Proprotein ConvertasesProteinsRegulationRiskRisk FactorsRoleSan FranciscoSerine ProteaseStructureStructure-Activity RelationshipSubtilisinsSynthesis ChemistrySystemTechniquesTestingTherapeuticTherapeutic antibodiesTrainingTranslational ResearchUniversitiesanalogbasechemical geneticsclinically relevantclinically significantdesigndrug discoveryextracellulargain of functionimprovedinhibitor/antagonistinterestkexinloss of functionloss of function mutationmutantnovel therapeuticsreceptor bindingscaffoldsecretion processsmall moleculetherapeutic developmenttrafficking
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease which regulates LDL cholesterol levels and, by extension, the development of atherosclerosis. Epidemiologic and genetic studies have provided strong evidence that mutations in PCSK9 are related to cardiovascular outcomes. Interestingly, the catalytic activity of the PCSK9 is not directly required for the PCSK9/LDL-receptor interaction. As such, this protein has become an exciting target for development of therapeutics to block this PCSK9/LDL-R interaction. This study proposes to evaluate the relationship between PCSK9 catalytic activity and the PCSK9/LDL-R interaction on a biochemical basis. In Aim 1, the study will engineer "electrophile-sensitive" PCSK9 analogs with rationally designed active site modifications that will
allow for specific and covalent binding of small molecule inhibitors with electrophilic handles. The catalytic activity of the ES-PCSK9 analogs, along with the ability of the small molecules to achieve specific inhibition, will be assessed in vitro. The ES-PCSK9 will be introduced in a cellular system, and the effects on LDL processing will be assessed. In Aim 2, the structure activity relationship of the specific inhibitors will be assessed. The study will test the hypothess that binding of inhibitor to the PCSK9 active site will cause allosteric inhibition of the PCSK9/LDLR interaction. In Aim 3, the role of intracellular and extracelullar PCSK9 to LDL regulation will be evaluated. The mechanisms of clinically significant polymorphisms will be assessed by introducing GOF and LOF mutations into ES-PCSK9. The possibility of dominant negative and dominant positive effects will be evaluated. In addition to the training in basic science and translational research through the conduct of the study, the applicant will undertake didactic instruction in synthetic chemistry and chemical biology techniques through auditing graduate courses offered at the University of California, San Francisco.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Small molecule allosteric inhibitors of PCSK9 processing to phenocopy cardioprotective genetic variants.
-
批准号:10747623
-
项目类别:
-
资助金额:$53.75万
-
财政年份:2023
-
负责人:John S Chorba
-
依托单位:
CSDE1 as a Post Transcriptional Regulator of the LDLR - Diversity Supplement
-
批准号:10635281
-
项目类别:
-
资助金额:$9.71万
-
财政年份:2022
-
负责人:John S Chorba
-
依托单位:
CSDE1 as a Post Transcriptional Regulator of the LDLR
-
批准号:10290273
-
项目类别:
-
资助金额:$63.46万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
Sequence Specific Inhibition of Protein Translation
-
批准号:10379318
-
项目类别:
-
资助金额:$20.19万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
-
批准号:10852687
-
项目类别:
-
资助金额:$9.34万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
CSDE1 as a Post Transcriptional Regulator of the LDLR
-
批准号:10640866
-
项目类别:
-
资助金额:$63.02万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
Sequence Specific Inhibition of Protein Translation
-
批准号:10196539
-
项目类别:
-
资助金额:$24.23万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
-
批准号:10598882
-
项目类别:
-
资助金额:$9.34万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
-
批准号:10370428
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
CSDE1 as a Post Transcriptional Regulator of the LDLR
-
批准号:10447206
-
项目类别:
-
资助金额:$62.7万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
-
批准号:10631047
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis
-
批准号:10215201
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2021
-
负责人:John S Chorba
-
依托单位:
Probing the multiple roles of the PCSK9 active site using chemical biology
-
批准号:9103195
-
项目类别:
-
资助金额:$18.13万
-
财政年份:2015
-
负责人:John S Chorba
-
依托单位:
Targeting the serine protease PCSK9 via covalent complementarity
-
批准号:8398870
-
项目类别:
-
资助金额:$5.77万
-
财政年份:2012
-
负责人:John S Chorba
-
依托单位:
海外基金